Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1649 drug-target rows in SSL view, for TSG = CHEK1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib CHEK1 PARP1 1
sunitinib CHEK1 MET 5
crizotinib CHEK1 MET 6
gemcitabine CHEK1 RRM1 6
bevacizumab CHEK1 VEGFA 3
gemcitabine CHEK1 TYMS 3
gemcitabine CHEK1 CMPK1 3
lurbinectedin, irinotecan CHEK1 TOP1 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CHEK1 VEGFA 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CHEK1 FGFR2 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CHEK1 ABL1 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CHEK1 FGFR2 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CHEK1 ABL1 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab CHEK1 TYMS 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab CHEK1 RRM1 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab CHEK1 CMPK1 3
cabozantinib CHEK1 MET 6
capecitabine CHEK1 TYMS 6
everolimus CHEK1 MTOR 6
ibrutinib CHEK1 BTK 6
nintedanib CHEK1 FGFR2 6
regorafenib CHEK1 FGFR2 6
regorafenib CHEK1 ABL1 6
sacituzumab govitecan CHEK1 TOP1 6
topotecan CHEK1 TOP1 6
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin CHEK1 VEGFA 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine CHEK1 VEGFA 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine CHEK1 TYMS 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine CHEK1 RRM1 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine CHEK1 CMPK1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 SMO 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 PIK3CA 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 MAP2K1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 SRC 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 MET 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 WEE1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 FGFR2 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 MAPK1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 AKT1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 BTK 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CHEK1 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 IGF1R 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 MET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 DHFR 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 FGFR2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CHEK1 ABL1 2
apatinib, irinotecan CHEK1 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CHEK1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CHEK1 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CHEK1 RRM1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CHEK1 CMPK1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 CHEK1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 CHEK1 DHFR 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CHEK1 MAP2K1 2
capecitabine, cisplatin CHEK1 TYMS 2
capecitabine, temozolomide CHEK1 TYMS 2
cft1946, trametinib, cetuximab CHEK1 MAP2K1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab CHEK1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab CHEK1 DHFR 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab CHEK1 RRM1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab CHEK1 CMPK1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study CHEK1 IGF1R 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study CHEK1 MTOR 2
cobimetinib, mehd7945a CHEK1 MAP2K1 2
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus CHEK1 MTOR 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib CHEK1 FGFR2 2
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan CHEK1 TOP1 2
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan CHEK1 FGFR2 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide CHEK1 TYMS 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide CHEK1 DHFR 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide CHEK1 TOP1 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib CHEK1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib CHEK1 DHFR 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib CHEK1 MAP2K1 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine CHEK1 DCK 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine CHEK1 RRM1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate CHEK1 FGFR2 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells CHEK1 SLC29A2 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells CHEK1 SLC29A1 2
mirdametinib, bgb-3245 CHEK1 MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed CHEK1 TYMS 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed CHEK1 DHFR 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed CHEK1 RRM1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed CHEK1 CMPK1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CHEK1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CHEK1 DHFR 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CHEK1 FGFR2 2
motexafin gadolinium, radiation therapy CHEK1 RRM2 2
nab-paclitaxel, gemcitabine CHEK1 TYMS 2
nab-paclitaxel, gemcitabine CHEK1 RRM1 2
nab-paclitaxel, gemcitabine CHEK1 CMPK1 2
nintedanib CHEK1 SRC 2
nintedanib, pembrolizumab CHEK1 SRC 2
nintedanib, pembrolizumab CHEK1 FGFR2 2
nivolumab, ipilimumab, cobimetinib CHEK1 MAP2K1 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu CHEK1 TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu CHEK1 RRM1 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu CHEK1 CMPK1 2
osimertinib, bevacizumab, osimertinib CHEK1 VEGFA 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed CHEK1 VEGFA 2
pembrolizumab, belzutifan, lenvatinib CHEK1 FGFR2 2
pembrolizumab, lenvatinib CHEK1 FGFR2 2
pemetrexed, bevacizumab CHEK1 VEGFA 2
pemetrexed, bevacizumab CHEK1 TYMS 2
pemetrexed, bevacizumab CHEK1 DHFR 2
pentostatin, cyclophosphamide, ss1(dsfv)pe38 - lot 073i0809, ss1(dsfv)pe38 - lot fil129j01 CHEK1 ADA 2
pharmacological study, romidepsin CHEK1 HDAC6 2
regorafenib, laboratory biomarker analysis CHEK1 FGFR2 2
regorafenib, laboratory biomarker analysis CHEK1 ABL1 2
rubitecan CHEK1 TOP1 2
selumetinib, medi4736, tremelimumab CHEK1 MAP2K1 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel CHEK1 TYMS 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel CHEK1 RRM1 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel CHEK1 CMPK1 2
temsirolimus CHEK1 MTOR 2
temsirolimus, laboratory biomarker analysis CHEK1 MTOR 2
tislelizumab, pemetrexed CHEK1 TYMS 2
tislelizumab, pemetrexed CHEK1 DHFR 2
tivantinib CHEK1 MET 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy CHEK1 TYMS 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy CHEK1 DHFR 2
binimetinib CHEK1 MAP2K1 6
bosutinib CHEK1 SRC 6
bosutinib CHEK1 ABL1 6
mycophenolic acid CHEK1 IMPDH1 6
pemetrexed CHEK1 TYMS 6
pemetrexed CHEK1 DHFR 6
pemigatinib CHEK1 FGFR2 6
ponatinib CHEK1 ABL1 6
romidepsin CHEK1 HDAC6 6
selumetinib CHEK1 MAP2K1 6
trastuzumab deruxtecan CHEK1 TOP1 4
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy CHEK1 VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy CHEK1 TYMS 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide CHEK1 VEGFA 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging CHEK1 TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat CHEK1 HDAC6 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat CHEK1 HDAC6 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide CHEK1 RRM2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery CHEK1 TYMS 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin CHEK1 TOP1 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin CHEK1 VEGFA 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin CHEK1 TYMS 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin CHEK1 RRM1 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin CHEK1 CMPK1 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis CHEK1 TYMS 1
7-hydroxystaurosporine, fluorouracil CHEK1 TYMS 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan CHEK1 TOP1 1
9-ing-41, retifanlimab, gemcitabine, abraxane CHEK1 TYMS 1
9-ing-41, retifanlimab, gemcitabine, abraxane CHEK1 RRM1 1
9-ing-41, retifanlimab, gemcitabine, abraxane CHEK1 CMPK1 1
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin CHEK1 TYMS 1
abemaciclib, bevacizumab CHEK1 VEGFA 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CHEK1 TOP1 1
abemaciclib, ly3023414, gemcitabine, capecitabine CHEK1 TYMS 1
abemaciclib, ly3023414, gemcitabine, capecitabine CHEK1 RRM1 1
abemaciclib, ly3023414, gemcitabine, capecitabine CHEK1 CMPK1 1
abraxane (nab-paclitaxel), gemcitabine CHEK1 TYMS 1
abraxane (nab-paclitaxel), gemcitabine CHEK1 RRM1 1
abraxane (nab-paclitaxel), gemcitabine CHEK1 CMPK1 1
adavosertib CHEK1 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy CHEK1 WEE1 1
adavosertib, radiation therapy CHEK1 WEE1 1
adavosertib, radiation therapy, temozolomide CHEK1 WEE1 1
adct-601, gemcitabine CHEK1 TYMS 1
adct-601, gemcitabine CHEK1 RRM1 1
adct-601, gemcitabine CHEK1 CMPK1 1
adebrelimab injection, apatinib mesylate tablets, carboplatin, cisplatin, etoposide CHEK1 TOP2A 1
adebrelimab, apatinib mesylate, etoposide, carboplatin CHEK1 TOP2A 1
adebrelimab, apatinib, tegafur CHEK1 TYMS 1
adebrelimab, carboplatin/cisplatin, etoposide, radiation therapy CHEK1 TOP2A 1
adebrelimab, radiation therapy, etoposide, carboplatin(ec) CHEK1 TOP2A 1
aee788, everolimus CHEK1 MTOR 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis CHEK1 TYMS 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CHEK1 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CHEK1 SRC 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CHEK1 BTK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CHEK1 ABL1 1
afatinib, irinotecan CHEK1 TOP1 1
ag-013736, gemcitabine, gemcitabine, placebo CHEK1 TYMS 1
ag-013736, gemcitabine, gemcitabine, placebo CHEK1 RRM1 1
ag-013736, gemcitabine, gemcitabine, placebo CHEK1 CMPK1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel CHEK1 TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel CHEK1 RRM1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel CHEK1 CMPK1 1
ags-1c4d4, gemcitabine CHEK1 TYMS 1
ags-1c4d4, gemcitabine CHEK1 RRM1 1
ags-1c4d4, gemcitabine CHEK1 CMPK1 1
ak104, ak104, gemcitabine, nab-paclitaxel CHEK1 TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel CHEK1 RRM1 1
ak104, ak104, gemcitabine, nab-paclitaxel CHEK1 CMPK1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine CHEK1 TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine CHEK1 RRM1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine CHEK1 CMPK1 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib CHEK1 TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib CHEK1 MAP2K1 1
albumin-bound paclitaxel (abi-007), gemcitabine CHEK1 TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine CHEK1 RRM1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.